Sam Schlessinger - Assertio Therapeutics Executive Counsel
| ASRT Stock | USD 0.91 0.03 3.41% |
Executive
Sam Schlessinger is Executive Counsel of Assertio Therapeutics
| Age | 42 |
| Phone | 224 419 7106 |
| Web | https://www.assertiotx.com |
Sam Schlessinger Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sam Schlessinger against Assertio Therapeutics stock is an integral part of due diligence when investing in Assertio Therapeutics. Sam Schlessinger insider activity provides valuable insight into whether Assertio Therapeutics is net buyers or sellers over its current business cycle. Note, Assertio Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Assertio Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sam Schlessinger over six months ago Disposition of 19404 shares by Sam Schlessinger of Assertio Therapeutics subject to Rule 16b-3 | ||
Sam Schlessinger over six months ago Disposition of 19404 shares by Sam Schlessinger of Assertio Therapeutics subject to Rule 16b-3 | ||
Sam Schlessinger over a year ago Acquisition by Sam Schlessinger of 283500 shares of Assertio Therapeutics at 0.79 subject to Rule 16b-3 | ||
Sam Schlessinger over a year ago Disposition of 38017 shares by Sam Schlessinger of Assertio Therapeutics subject to Rule 16b-3 |
Assertio Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0796) % which means that it has lost $0.0796 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.384) %, meaning that it created substantial loss on money invested by shareholders. Assertio Therapeutics' management efficiency ratios could be used to measure how well Assertio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dan MBA | Amphastar P | N/A | |
| Ilanit Allen | Citius Pharmaceuticals | N/A | |
| Cassie Jung | Aquestive Therapeutics | 45 | |
| Myron MD | Citius Pharmaceuticals | 65 | |
| MP MBA | Amphastar P | N/A | |
| Cheryl Ball | Lantheus Holdings | N/A | |
| Charles Parker | Traws Pharma | 45 | |
| Todd Lopeman | Dynavax Technologies | N/A | |
| Alan Lader | Citius Pharmaceuticals | N/A | |
| Sherry Korczynski | Aquestive Therapeutics | 55 | |
| Jamie Spaeth | Lantheus Holdings | 43 | |
| Dorothy Barr | Lantheus Holdings | N/A | |
| Ernest Toth | Aquestive Therapeutics | 66 | |
| Nikolas Burlew | Citius Pharmaceuticals | N/A | |
| Catherine MS | Citius Pharmaceuticals | N/A | |
| Victor MD | Traws Pharma | 56 | |
| Christopher Mutz | ANI Pharmaceuticals | 54 | |
| Rong MS | Amphastar P | 66 | |
| Jeff Coon | Dynavax Technologies | 62 | |
| Melina PharmD | Aquestive Therapeutics | 42 | |
| Robert MD | Traws Pharma | 73 | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.0796 |
Assertio Therapeutics Leadership Team
Elected by the shareholders, the Assertio Therapeutics' board of directors comprises two types of representatives: Assertio Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Assertio. The board's role is to monitor Assertio Therapeutics' management team and ensure that shareholders' interests are well served. Assertio Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Assertio Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jack Hoblitzell, VP Operations | ||
| MD MBA, Senior Medical | ||
| Brendan OGrady, CEO Director | ||
| Ajay Patel, Executive CFO | ||
| Sam Schlessinger, Executive Counsel | ||
| Molly Dir, Senior Administration | ||
| Bill Iskos, Senior Operations | ||
| Paul Schwichtenberg, Executive Officer | ||
| Jeff Christensen, Senior Commercial | ||
| Heather Mason, Interim Director | ||
| Mary Pietryga, Executive Officer | ||
| Daniel Peisert, CEO Pres |
Assertio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Assertio Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.0796 | ||||
| Profit Margin | (0.37) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 26.86 M | ||||
| Shares Outstanding | 96.24 M | ||||
| Shares Owned By Insiders | 2.51 % | ||||
| Shares Owned By Institutions | 26.94 % | ||||
| Number Of Shares Shorted | 4.71 M | ||||
| Price To Earning | 4.93 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.